ArticleClinicoEconomics and outcomes research : CEOR2020

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.

Josep Maria Ribera Santasusana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.